Company / Operating Cash Flow
AXIM BIOTECHNOLOGIES, INC. Operating Cash Flow History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$1.0M
FY2023
5-year range
-$4.8M / -$1.0M
FY2019-FY2023
Trend
+49.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 9 years, ranging from -$5M in FY2018 to $25,143 in FY2012.
Based on SEC 10-K filings.
-$1M in FY2023.
Improved from -$5M to -$1M over the past 5 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, operating cash flow increased 49.6% year-over-year.
- Peak operating cash flow was recorded in FY2012.
- Lowest operating cash flow in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$1.0M | +49.6% |
| FY2022 | -$2.0M | +57.8% |
| FY2018 | -$4.8M | -57.2% |
| FY2017 | -$3.1M | -138.1% |
| FY2016 | -$1.3M | +15.9% |
| FY2015 | -$1.5M | -4561.6% |
| FY2013 | -$33.0K | -231.3% |
| FY2012 | $25.1K | +522.7% |
| FY2011 | $4.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026